A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Study the Efficacy and Safety of MK0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women

Trial Profile

A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Study the Efficacy and Safety of MK0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Alendronic acid/colecalciferol (Primary) ; Osteoporosis therapies
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Apr 2012 Planned number of patients changed from 800 to 840 as reported by European Clinical Trials Database record.
    • 17 Dec 2009 Planned end date changed from 1 Jan 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top